HCG Divests Fertility Business for ₹37.64 Crore

HealthCare Global Enterprises Limited has approved the divestment of its entire equity shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I and its nominee. The Board of Directors and Audit Committee granted approval during meetings held on May 19, 2026. The transaction is valued at INR 37,64,44,788 and is expected to be completed within 4-5 weeks from the date of the announcement, subject to the terms of the Share Purchase Agreement (SPA). BACC is engaged in fertility and reproductive healthcare services, which the company identified as a non-core business activity.

Transaction Details

The proposed transaction is a related party transaction, as the buyer, Inviga Healthcare Fund I, is controlled by Dr. B.S. Ajaikumar, the Promoter and Non-Executive Chairman of the company. The deal was approved following a competitive process. The company stated that the transaction is being undertaken on an arm's length basis, with the consideration based on a valuation report by an independent third-party valuer.

Financial Impact of BACC

For the financial year 2025-26, BACC reported revenue from operations of INR 60.45 crore, which accounted for 4.45% of the company's standalone revenue. The net worth of BACC as of March 31, 2026, stood at INR 17.53 crore, representing 1.09% of the company's standalone net worth. The divestment is expected to facilitate greater operational focus, allowing the company to reinvest capital in high-growth areas such as cancer services.

BACC Financial Metrics (FY 2025-26)

The following table summarises BACC's key financial metrics relative to HCG's standalone figures:

Metric:	Amount (INR in Crores)	% of HCG Standalone
Revenue From Operations	60.45	4.45%
Net Worth	17.53	1.09%

Payment Structure

The consideration of INR 37,64,44,788 will be paid in two tranches. An aggregate amount of INR 28,23,33,591 is payable on the date of closing. The remaining deferred consideration of INR 9,41,11,197 will be paid within 18 months of the signing of the SPA.

HealthCare Global Enterprises Limited announced the launch of its new comprehensive cancer hospital in Hebbal, North Bengaluru. The facility, with a capacity of up to 132 beds, strengthens access to advanced oncology care in the region. The project represents an investment of approximately INR 129 Crores, financed through a mix of debt and internal accruals.

Advanced Technology and Infrastructure

The new hospital introduces Karnataka's first Elekta Unity MR-Linac, one of the world's most advanced precision radiation therapy platforms. This technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. The facility is designed as a full-spectrum oncology centre, bringing together diagnosis, treatment, and recovery support under one roof.

Key Facility Details

The following table summarises the key infrastructure and financial details of the new facility:

Particulars:	Details
Location:	Byatarayanapura, Hebbal, North Bengaluru
Bed Capacity:	Up to 132 beds
Investment Required:	Approximately INR 129 Crores
Mode of Financing:	Mix of Debt and Internal Accruals
Key Technology:	Elekta Unity MR-Linac (First in Karnataka)

Strategic Rationale

The establishment of the hospital addresses the long-standing need for a dedicated and comprehensive cancer care facility in North Bengaluru. Previously, patients often had to commute across Bengaluru city for treatment. The new facility in Byatarayanapura bridges this gap by providing personalised and patient-focused cancer care close to home, supported by advanced technology and clinical expertise.